rs63749795 变种增加了子宫内膜异位症的风险:一项遗传关联研究
Niloofar Nazarikhah1, Mohammad Javad Mokhtari1
1Department of Biology, Zarg.C., Islamic Azad University, Zarghan, Islamic Republic of Iran.
Personalized medicine
|February 24, 2026
概括
这项研究研究了MutL同源1 (MLH1) 单核酸多态 (SNP) 和子宫内膜异位症风险. MLH1 rs63749795的多态性与增加子宫内膜异位症的易感性有关,而TC类型则提供了保护.
科学领域:
- 遗传学 遗传学 是一个
- 妇科 妇科 妇科 妇科
- 分子生物学分子生物学
背景情况:
- 子宫内膜异位症是一种复杂的妇科疾病.
- 遗传因素与子宫内膜异位症的发展有关.
- 具体MLH1基因多态的作用需要进一步研究.
研究的目的:
- 检查MLH1SNP (rs63749795和rs63749820) 与子宫内膜异位症风险之间的关联.
- 为了确定潜在的子宫内膜异位症易感性的遗传标记.
主要方法:
- 一项涉及150名子宫内膜异位症患者和150名健康对照者的病例控制研究.
- 使用四级原始ARMS-PCR.MLH1多态的基因定型.
- 统计分析包括赔率比率和置信区间.
主要成果:
- MLH1 rs63749820多态性没有与子宫内膜异位症风险显著相关.
- MLH1 rs63749795多态,特别是CT基因型,与增加子宫内膜异位症易感性 (OR=2.42,p=0.001) 有显著的关联.
- 单元型分析表明,CC和TT与风险增加有关,而TC单元型表现出保护作用 (OR=0.50,p=0.0003).
结论:
- 这项研究提供了第一个证据,表明MLH1rs63749795多态性和子宫内膜异位症易感性之间存在显著的关联.
- MLH1 rs63749795多态可能作为子宫内膜异位症的潜在遗传标志物.
- 特定的MLH1单元类型,如TC,可能会对子宫内膜异位症产生保护作用.
更多相关视频
相关概念视频
Genome-wide Association Studies-GWAS
15.9K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
15.9K
Non-LTR Retrotransposons
13.5K
As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...
13.5K
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
26
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
26
Mismatch Repair
6.8K
Organisms are capable of detecting and fixing nucleotide mismatches that occur during DNA replication. This sophisticated process requires identifying the new strand and replacing the erroneous bases with correct nucleotides. Mismatch repair is coordinated by many proteins in both prokaryotes and eukaryotes.
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
6.8K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
45
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
45


